From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of Brutontyrosinekinase (BTK), with IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Tolebrutinib exhibits efficacy in central nervous system immunity. Tolebrutinib can be used for the research of multiple sclerosis (MS) .
ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Brutontyrosinekinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM .
BTK degrader-1 (compound 1) is a Bruton’s tyrosinekinase (BTK) bifunctional degrader that can be conjugated with CD79b. BTK degrader-1 (compound 1) has anti-tumor effect .
(±)-Zanubrutinib ((±)-BGB-3111) is the racemate of Zanubrutinib (HY-101474A). (±)-Zanubrutinib inhibits Bruton's tyrosinekinase (Btk) with an IC50 of 0.63 nM .
Cinsebrutinib is a Bruton's tyrosinekinase inhibitor, extracted from patent WO2021207549 (compound 5-6). Cinsebrutinib has the potential for cancer study.
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosinekinase on chromosome X (BMX) that targets Cys 496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosinekinase(BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton’s TyrosineKinase (BTK), with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.
(R)-Zanubrutinib-d5 is deuterium labeled (R)-Zanubrutinib. (R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Brutontyrosinekinase (BTK) inhibitor.
(R)-NX-2127 (compound 28) is an orally active Bruton’s TyrosineKinase (Btk) degrader. (R)-NX-2127 degrades IKZF1 and IKZF3 by molecular glue interactions with the cereblon E3 ubiquitin ligase complex .
Ibrutinib-MPEA (Compound 20) is ibrutinib derivative. Ibrutinib is a covalent and irreversible inhibitor of Bruton's tyrosinekinase (BTK) that has been used to treat haematological malignancies .
BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosinekinase (BTK) with IC50s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia .
Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosinekinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling .
Branebrutinib (BMS-986195) is a highly potent, selective covalent, irreversible inhibitor of Bruton’s tyrosinekinase(BTK), with an IC50 of 0.1 nM . Branebrutinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Tirabrutinib (ONO-4059) hydrochloride is an orally active Bruton’s TyrosineKinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC50 of 6.8 nM. Tirabrutinib hydrochloride irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib hydrochloride can be used in studies of autoimmune diseases and hematological malignancies .
Tirabrutinib (ONO-4059) is an orally active Bruton’s TyrosineKinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC50 of 6.8 nM. Tirabrutinib irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib can be used in studies of autoimmune diseases and hematological malignancies .
BTK ligand 1 (compound 1) is a ligand targeting Bruton’s tyrosinekinase (Btk). BTK ligand 1 can combine with E3 ligase ligand (Ligand for E3 Ligase) through PROTAC Linker to form PROTAC. PROTACs targeting Btk can be used in the study of chronic lymphocytic leukemia (CLL) and other BK cell malignancies .
BTK-IN-15 (compound 42) is a potent Bruton's tyrosinekinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits BTK with an IC50 value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis .
Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosinekinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease .
Remibrutinib, is a potent and orally active brutontyrosinekinase (BTK) inhibitor with an IC50 value of 1 nM. Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood . Remibrutinib has the potential for Chronic urticaria (CU) treatment .
BTK-IN-6 is a potent inhibitor of Bruton's TyrosineKinase (BTK). BTK is a member of the Tec family of tyrosinekinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8) .
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosinekinase (BTK) and its C481 mutant, with IC50 values of 0.7 and 0.8 nM for BTK and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosinekinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .
BGB-8035 is an orally active, highly selective bruton's tyrosinekinase (BTK) inhibitor with IC50s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research .
Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Brutontyrosinekinase (BTK) inhibitor. With an IC50 of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR). Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis .
Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosinekinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research .
ACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Brutontyrosinekinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM[1][2].
The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Baculovirus, His) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells , with N-10*His labeled tag. The total length of BTK Protein, Human (Baculovirus, His) is 659 a.a., with molecular weight of ~78.3 kDa.
(R)-Zanubrutinib-d5 is deuterium labeled (R)-Zanubrutinib. (R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Brutontyrosinekinase (BTK) inhibitor.
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosinekinase (BTK) and its C481 mutant, with IC50 values of 0.7 and 0.8 nM for BTK and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .
ACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Brutontyrosinekinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM[1][2].
BTK Antibody (YA816) is a non-conjugated and Mouse origined monoclonal antibody about 76 kDa, targeting to BTK (5B12). It can be used for WB,IP assays with tag free, in the background of Human.
Phospho-BTK(Y223) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 76 kDa, targeting to Phospho-BTK(Y223). It can be used for WB, IHC-P, IHC-F, ICC, IF assays with tag free, in the background of Human.
